EU Approves Enhertu Plus Pertuzumab as First-Line Treatment for HER2-Positive Metastatic Breast Cancer
AZN is trading near its 52-week low of $146.1 (11% above the low).
Summary
AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab won EU approval for first-line HER2-positive metastatic breast cancer, backed by a 40.7-month median PFS versus 26.9 months for standard of care. A $100 million milestone payment to Daiichi Sankyo is now due.
Key Events · Product Development and Regulatory · AZN
-
EU Approval for 1st-Line HER2+ mBC
The European Commission approved Enhertu plus pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer, the first new regimen in this setting in more than a decade.
-
DESTINY-Breast09 Efficacy Data
Median PFS of 40.7 months vs 26.9 months for THP (HR 0.56; 95% CI 0.44-0.71; p<0.00001), a 44% reduction in risk of disease progression or death.
-
$100M Milestone Payment Due
Following EU approval, AstraZeneca owes Daiichi Sankyo a $100 million milestone payment for the first-line unresectable or metastatic HER2-positive breast cancer indication.
-
ESMO Guideline Inclusion
Enhertu plus pertuzumab is now included in ESMO Clinical Practice Guidelines as a Category IA first-line treatment option regardless of hormone receptor status.
Analysis · AZN · Life Sciences
The European Commission has approved Enhertu plus pertuzumab, marking the first new first-line regimen for HER2-positive metastatic breast cancer in over a decade. Compelling data from DESTINY-Breast09 show a median progression-free survival of 40.7 months versus 26.9 months for the prior standard of care, translating to a 44% reduction in the risk of disease progression or death. This approval expands Enhertu's addressable market into the front-line setting across the EU and triggers a $100 million milestone payment to Daiichi Sankyo. While the milestone is modest for a company of AstraZeneca's scale, the approval strengthens a key oncology franchise and supports the narrative of Enhertu becoming the new standard of care.
How filings like this one have moved
In the 30 days to Sep 7, 2026, 36.5% of the 1935 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $162.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $251.4B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.